Fig. 1 | Gene Therapy

Fig. 1

From: Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice

Fig. 1

Administration of 5 × 109 vg/mouse AAV2/8-HLP-hINSco restores normoglycaemia in chemically induced diabetic C57BL/6 mice but not in naturally diabetic NOD mice. C57BL/6 male mice (a), rendered diabetic with streptozotocin (40 mg/kg i.p. for 5 days), or NOD female mice (b), tested positive for diabetes more than three consecutive times, were treated with AAV2/8-insulin therapy (indicated as AAV2/8) (day 0). Blood glucose levels were then monitored over time (a, b top panels). Plasma human C-peptide levels of C57BL/6 (a, bottom panel) and NOD (b, bottom panel) mice were measured over time after AAV2/8-HLP-hINSco injection. c Average genome copy number of virus per liver cell at the end of the 30-day experiments. d Transgenic human insulin mRNA expression in the treated C57BL/6 and NOD mice livers relative to C57BL/6 mice’s levels at the end of the 30-day experiments. Data shown are expressed as mean ± SE and are representative of two independent experiments

Back to article page